TY - JOUR A1 - Fleischmann, Maximilian A1 - Chatzikonstantinou, Georgios A1 - Fokas, Emmanouil A1 - Wichmann, Jörn A1 - Christiansen, Hans A1 - Strebhardt, Klaus A1 - Rödel, Claus A1 - Tselis, Nikolaos A1 - Rödel, Franz T1 - Molecular markers to predict prognosis and treatment response in uterine cervical cancer T2 - Cancers N2 - Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis. KW - cervical cancer KW - predictive KW - prognostic KW - molecular marker KW - biomarker KW - outcome KW - survival KW - response KW - chemoradiotherapy Y1 - 2021 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/82277 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-822772 SN - 2072-6694 VL - 13 IS - 22, art. 5748 SP - 1 EP - 28 PB - MDPI CY - Basel ER -